This is a Phase III randomly assigned, neither you nor the study doctors know who gets the real treatment, positive controlled study to measure the how well it works, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus dummy treatment (placebo) in combination with R-GemOx in patients with R/R DLBCL.
Official registry: https://clinicaltrials.gov/study/NCT07409428 · Hutchmed · enrollment listed as 240
Phase 3: this treatment already looked useful in smaller studies. Now it is tested in a large group, often against standard care or a dummy treatment, to see if it should be approved.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are HMPL-760, HMPL-760 Placebo, or R-GemOx. The registry lists allocation as randomized. This is a Phase III randomly assigned, neither you nor the study doctors know who gets the real treatment, positive controlled study to measure the how well it works, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus dummy treatment (placebo) in combination with R-GemOx in patients with R/R DLBCL.
They plan to enroll about 240 people at 51 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: HMPL-760, HMPL-760 Placebo, R-GemOx
Primary outcome (registry wording): Progression-free survival (PFS)
Dongmei Chen, CPL
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
NCT00177268 · Official ClinicalTrials.gov record · University of Pittsburgh
Background The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these methods in a natural history study can help identify processes involved in disease progression, and possibly lead to the discovery or validation of treatment targets.
NCT00923507 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.
NCT01793168 · Official ClinicalTrials.gov record · Sanford Health
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary